Prevalence of metallo-B-lactamase acquired genes among Carbapenems susceptible and resistant Gram-negative clinical isolates

Abstract

The emergence and rapid spread of lllti-rm, bla-vm, and bla-ppm metallo-beta- lactamase (MBL) producing Gram-negative bacteria causing nosocomial infections are of concern worldwide due to limited treatment options. The aim of this study is to determine the prevalence of MBl.s resistance genesby multiplex PCR method using three sets of primers, among 200 different clinical isolates of Gram-negative bacterial isolates (lilrobaeler syrp, £00//,' fir/erafiacler sop, Kp/ream/lllu; flaemgqhosa l?!111'rad1d.'s; a/10'/§;'a@,1an3). 100 sensitive and the other 100 resistant to Carbapenems collected from different hospitals, Khartoum State — Sudan during 2015 to 2016. Based on PCR assays, 72 (3 6.1 %) out of 200 Gram negative clinical isolates, were positive for MBLs genes. Out of 10o Carbapeuems, sensitive bacterial isolates (27%) were positive for MBLs, while among 100 Carbapenems resistant bacteria isolates (45%) were positive for MBls resistance genes. There is statistical significant association between the antimicrobial susceptibility and the The ‘t "1 Annual Conference Mm‘ r,s.93-4‘ l-1-ll-ll "4-b-*1) J-53»- Ministry Of Higher Education (4,-3=-ll ¢-Hit: uh!‘ rem‘ U1!) &Scientific Research [GCNU‘t] pY~ ‘V/\ \_‘/\ ~-‘\ PCR result p-value (0.008) (p<.05). Verona integron metallo beta lactamase (Vllll) gene was the most frequent, detected in 28 (38.9%) out of 72 positive lYlBl.s genes, followed by imipenemase (llllP) which detected in 19(26.4%). Statistical significant association was found between susceptibility and these lllBl.s genes with p-value of (0.03). E colis the predominant isolates detected harboring lllBbs genes 26 (36%), followed by If aemgvhosa 2s(3z%), K. ,0/1:1/mo/uiae 2o(2s%), R m1}alt1Zl¢2(2.s%) and If va/ganLv1(1.4%). While there is no statistical significant difference between the lllBl.s genes and carbapenem sensitive & resistant, clinical isolates p-value (0.275). ldentification of lllBLs producing strains and taking efforts to reduce the rate of transfer of these genes between different strains is essential for optimization of therapy and improves of patient outcomes.